Monash IVF Group
MVF.ASXHealth Care
Provider of assisted reproductive services and ultrasound services.
Market Data
$0.710
-0.0%$276.6M
18.4x
$0.039
0.00%
-0.0%
Latest Earnings
1H26 Appendix 4D and Financial Report
26 February 2026
Monash IVF Group reported 1H26 underlying NPAT of $10.4M (down 34% on pcp) at the upper end of November 2025 guidance, with revenue declining 1.8% to $137.9M due to softness in Australian IVF market share and volumes. The company maintained FY26 guidance of $20M underlying NPAT and declared a 1.2 cent fully franked interim dividend. Key points: Underlying NPAT of $10.4M at upper end of November 2025 guidance; Strong international growth with 14.3% revenue increase and 6.9% stimulated cycle growth; Genetics and Ancillary income growth of $2.5M driven by increased PGT activity
Recent Announcements
1H26 Appendix 4D and Financial Report
Monash IVF Group reported 1H26 underlying NPAT of $10.4M (down 34% on pcp) at the upper end of November 2025 guidance, with revenue declining 1.8% to $137.9M due to softness in Australian IVF market share and volumes. The company maintained FY26 guidance of $20M underlying NPAT and declared a 1.2 cent fully franked interim dividend. Key points: Underlying NPAT of $10.4M at upper end of November 2025 guidance; Strong international growth with 14.3% revenue increase and 6.9% stimulated cycle growth; Genetics and Ancillary income growth of $2.5M driven by increased PGT activity
FY26 Half Year Results Release
Monash IVF Group announced it will release its FY26 half year financial results on Thursday 26 February 2026. This is just a pre-announcement notice with no financial results or guidance provided yet. The company continues to operate as a leading provider of assisted reproductive services across Australia and Southeast Asia. Key points: Established provider of assisted reproductive services across multiple markets; Geographic diversification with operations in Australia, Singapore, Malaysia and Indonesia; Also provides specialist women's imaging and diagnostic services
MVF FY25 Appendix 4E and Financial Report
Monash IVF Group delivered FY25 revenue growth of 6.7% to $271.9m and underlying EBITDA growth of 5.6% to $66.3m, with underlying NPAT declining 8.1% to $27.4m primarily due to higher finance costs and non-recurring items. The company swung to a net profit of $25.7m (vs FY24 loss of $5.9m) following resolution of the NiPGT class action settlement, though underlying earnings were impacted by weaker international volumes and clinic incidents. Guidance remains on track with updated FY25 profit guidance met. Key points: Revenue growth of 6.7% to $271.9m driven by both Australian (6.2%) and International segments (12.9%); Underlying EBITDA growth of 5.6% to $66.3m demonstrates operational leverage despite market headwinds; Swung to net profit of $25.7m from FY24 loss of $5.9m following NiPGT class action settlement resolution
Get real-time alerts for MVF
Receive AI-powered earnings summaries and instant notifications when Monash IVF Group releases results.
Register Free